Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05472818 · ClinicalTrials.gov registry record · Early Phase 1
SV2A Density Cannabis Use Disorder
A Early Phase 1 study of Healthy and Cannabis Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT05472818: Recruiting Early Phase 1 study of Healthy and Cannabis Use Disorder, sponsored by Yale University.
NCT05472818 is a Early Phase 1 study of Healthy and Cannabis Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 51 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05472818, a Early Phase 1 study of Healthy and Cannabis Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence. Finally, the relationship between hippocampal \[11C\]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored.
Primary Outcome
Hippocampal SV2A synaptic density will be measured using \[11C\]APP311 (UCB-J).
Conditions Studied
Interventions
- DRUG [11C]APP311
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2032-05 |
| Phase | Early Phase 1 |
What NCT05472818 shows while recruiting
NCT05472818 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [11C]APP311 is the first listed.
NCT05472818 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05472818 about?
NCT05472818 is a clinical study titled "SV2A Density Cannabis Use Disorder". The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \[11C\]APP-311/\[11C\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to h...
What is the current status of trial NCT05472818?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 51 participants. The study started on 2022-04-12. Estimated completion is 2032-05.
What conditions does trial NCT05472818 study?
This clinical trial studies the following conditions: Healthy, Cannabis Use Disorder.
What interventions are being tested in trial NCT05472818?
The interventions under investigation include: [11C]APP311 (DRUG).
Who is sponsoring clinical trial NCT05472818?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05472818 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05472818's enrollment target sits among peer trials
51 446th of 1090 higher than 644 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
-
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI